

1 **Curing genetic skin disease through altered replication stress response**

2

3 Toshinari Miyauchi¹, Shotaro Suzuki¹, Masae Takeda¹, Jin Teng Peh¹, Masayuki Aiba¹,

4 Ken Natsuga¹, Yasuyuki Fujita¹, Takuya Takeichi², Taiko Sakamoto³, Masashi

5 Akiyama², Hiroshi Shimizu¹ & Toshifumi Nomura^{1*}

6

7 ¹ Department of Dermatology, Faculty of Medicine and Graduate School of Medicine,

8 Hokkaido University, Sapporo, Japan

9 ² Department of Dermatology, Nagoya University Graduate School of Medicine,

10 Nagoya, Japan

11 ³ Sakamoto Clinic, Fujieda, Japan

12

13 ***Correspondence:** Toshifumi Nomura, MD, PhD

14 Department of Dermatology, Faculty of Medicine and Graduate School of Medicine,

15 Hokkaido University

16 North 15 West 7, Kita-ku, Sapporo 060-8638, Japan

17 Tel: +81-117067387

18 Fax: +81-117067820

19 E-mail: nomura@huhp.hokudai.ac.jp

20

21 **Competing Interests Declaration**

22 The authors declare no competing interests.

23

24

25 **Summary**

26 **Revertant mosaicism, or ‘natural gene therapy’, refers to the spontaneous *in vivo***
27 **reversion of an inherited mutation in a somatic cell¹. Only ~50 human genetic**
28 **disorders exhibit revertant mosaicism, implicating a distinctive role played by**
29 **mutant proteins in somatic correction of a pathogenic germline mutation².**
30 **However, the process by which mutant proteins induce somatic genetic reversion**
31 **in these diseases remains unknown. Here we show that heterozygous pathogenic**
32 ***CARD14* mutations causing autoinflammatory skin diseases, including psoriasis**
33 **and pityriasis rubra pilaris, are repaired mainly via homologous recombination.**
34 **Rather than altering the DNA damage response to exogenous stimuli such as X-**
35 **irradiation or etoposide treatment, mutant *CARD14* increased DNA double-strand**
36 **breaks under conditions of replication stress. Furthermore, mutant *CARD14***
37 **suppressed new origin firings without promoting crossover events in the**
38 **replication stress state. Together, these results suggest that mutant *CARD14* alters**
39 **the replication stress response and preferentially drives break-induced replication**
40 **(BIR), which is generally suppressed in eukaryotes³. Our results highlight the**
41 **involvement of BIR in reversion events, thus revealing a previously undescribed**
42 **role of BIR that could potentially be exploited to develop therapeutics for**
43 **currently intractable genetic diseases.**

44

45 Eukaryotic genomes are inevitably challenged by extrinsic and intrinsic stresses that
46 threaten genome integrity. DNA double-strand breaks (DSBs) are the most toxic and
47 mutagenic of DNA lesions⁴⁻⁶, arising both exogenously as a consequence of exposure to
48 ionising radiation (IR) and certain chemicals, and endogenously as a result of
49 replication stress or reactive oxygen species. Homologous recombination (HR) is a
50 crucial pathway involved in DSB repair and replication stress response (RSR)⁷⁻⁹. HR is
51 generally regarded as a genetically silent event in mitotic cells because it preferentially
52 occurs between sister chromatids following chromosomal replication. However, if HR
53 occurs via a homologous chromosome, it can lead to loss of heterozygosity (LOH),
54 which contributes to cancer initiation and progression¹⁰, tissue remodelling^{11,12} and,
55 notably, somatic genetic rescue events (referred to as ‘revertant mosaicism [RM]’) in
56 Mendelian diseases¹³. In particular, in some genetic skin diseases, each patient develops
57 dozens to thousands of revertant skin patches where a heterozygous pathogenic
58 germline mutation is reverted via LOH¹⁴⁻¹⁸, suggesting that HR may be enhanced in
59 mutant keratinocytes, the major cells of the epidermis. Manipulating HR to induce the
60 reversion of disease-causing mutations may potentially benefit patients with various
61 genetic diseases for which only symptomatic treatment is currently available. However,
62 the process by which mutant proteins induce increased rates of HR in these diseases
63 remains unknown.

64 Caspase recruitment domain-containing protein 14 (CARD14) is a scaffold molecule
65 predominantly expressed in keratinocytes. Heterozygous gain-of-function mutations in
66 *CARD14* lead to CARD14-associated papulosquamous eruption (CAPE), a disease
67 spectrum that includes psoriasis and pityriasis rubra pilaris¹⁹. Mutant CARD14 (mut-
68 CARD14) triggers the activation of nuclear factor (NF)- κ B signalling²⁰ with the

69 subsequent disruption of skin homeostasis, inflammation, and hyperproliferation of
70 keratinocytes, which are the canonical pathways implicated in psoriasis²¹.

71 Here, we present an initial evidence indicating HR-induced RM in CAPE. We aimed
72 to elucidate the molecular mechanisms underlying this self-healing phenomenon by
73 analysing the impact of mut-CARD14 on DNA damage and replication stress, as well as
74 the response to these events. We identified that mut-CARD14 may play an important
75 role in genetic reversion by enhancing BIR under replication stress.

76

77 **Results**

78 **Identification of RM in CAPE**

79 We analysed 2 unrelated Japanese patients with CAPE presenting with erythroderma
80 (generalised red skin) since birth. Case 1, a 60-year-old man, and Case 2, a 27-year-old
81 woman²², were heterozygous for c.356T>C (p.M119T) and c.407A>T (p.Q136L) in
82 *CARD14*, respectively (Fig. S1a-f). We noted numerous disseminated normal-appearing
83 skin areas in Case 1 and several clinically unaffected spots on the left leg of Case 2
84 (Fig. 1a and Fig. S1g-k). A skin biopsy revealed that these spots were histologically
85 normalised (Fig. 1b and Fig. S1l-n). Notably, the mutations reverted to wild-type in the
86 epidermis of all examined spots (6 of 6) but not in the dermis (Fig. 1c and Fig. S2a). To
87 address the mechanisms underlying this reversion, we performed a whole-genome
88 oligo-single nucleotide polymorphism (SNP) array analysis using genomic DNA from
89 each epidermis. Notably, copy-neutral LOH (cn-LOH), extending from breakpoints
90 proximal to *CARD14*, to the telomere on chromosome 17q, were identified in 4 of 6
91 revertant spots (Fig. 1d and Fig. S2b, c). Varying initiation sites of cn-LOH excluded
92 the possibility of simple genetic mosaicism. Notably, 1 of 3 revertant spots in Case 1

93 showed a different cn-LOH on chromosome 9q (Fig. S2d). Furthermore, Case 1 had
94 developed multiple skin tumours^{23,24}, including squamous cell carcinomas (SCCs)
95 which harbour chromosomal aberrations, such as LOH and trisomy (Fig. S2e, f).
96 Because HR events that are generally rare in most genetic skin diseases were frequently
97 observed in these CAPE patients, we inferred that mut-CARD14 may induce an
98 increase in the rate of HR, which potentially leads to RM and carcinogenesis (Fig. S1o).

99

100 **No direct effect of mutant CARD14 on DDR**

101 To examine the effects of mut-CARD14 on HR, we generated U2OS cell lines which
102 express FLAG-tagged wild-type (wt-), or mut-CARD14, only when doxycycline (Dox)
103 is present (Fig. 2a, b and Fig. S3a-c). To determine whether mut-CARD14 directly
104 increases DSBs, the levels of phosphorylated histone H2AX (γ H2AX), a major marker
105 of large chromatin domains surrounding DSBs, were quantified in these cell lines.
106 However, no significant increase in γ H2AX levels was detected in any of the cell lines
107 following Dox stimulation (Fig. 2c). To address whether mut-CARD14 alters DNA
108 damage response (DDR) to exogenous DSBs, we monitored γ H2AX levels as well as
109 the phosphorylation levels of 53BP1 and RPA2, markers for non-homologous end
110 joining and HR, respectively²⁵⁻²⁷, after exposing the cell lines to IR or etoposide. Mut-
111 CARD14 did not enhance HR in the repair of exogenous DSBs (Fig. S4a-d). To further
112 examine whether mut-CARD14 increases HR in DDR, we performed an enhanced
113 green fluorescent protein (EGFP)-based reporter assay in which a DSB induced by the
114 endonuclease I-SceI followed by HR leads to generation of EGFP-positive cells (Fig.
115 S5a)²⁸. Again, neither wt-CARD14 nor mut-CARD14 caused a significant increase in

116 HR frequency (Fig. S5b-f). These findings suggest that mut-CARD14 does not
117 preferentially increase either DNA damage or HR frequency in the DSB repair pathway.

118

119 **Mutant CARD14 alters RSR**

120 Replication stress, especially following prolonged stalling, may cause DNA replication
121 fork collapse, leading to DSBs⁶. HR promotes the restart of stress-induced stalled and
122 collapsed replication forks⁸. Therefore, we next sought to address whether mut-
123 CARD14 causes replication stress and alters RSR. To this end, we first performed a
124 fluorescence-activated cell sorting (FACS)-based cell cycle analysis using the U2OS
125 cell lines. However, mut-CARD14 did not alter cell cycle distribution (Fig. S6a, b).
126 This was further confirmed via DNA fibre analysis, in which mut-CARD14 neither
127 affected fork speed nor increased stalled fork frequency (Fig. S6c-g). Thus, mut-
128 CARD14 did not result in replication stress per se.

129 To address whether mut-CARD14 increases DSBs under conditions of replication
130 stress, we treated the cell lines with hydroxyurea (HU) and monitored γ H2AX levels up
131 to 48 h after treatment. Notably, mut-CARD14 cell lines with Dox showed higher levels
132 of γ H2AX than those without Dox at 36 h and 48 h, whereas wt-CARD14 cell lines
133 showed no difference at all time points (Fig. 2d). We performed the same analysis using
134 aphidicolin (APH), which also caused similar differences in γ H2AX levels based on
135 mut-CARD14 expression (Fig. S6h). In both analyses, no obvious difference in γ H2AX
136 levels was detected 24 h following treatment with HU or APH. Collectively, these
137 results suggest that mut-CARD14 expression leads to fork instability following
138 prolonged replication fork stalling but does not increase DSBs following short-term
139 fork stalling.

140 We next sought to clarify whether mut-CARD14-induced stalled fork instability is
141 mediated by the NF- κ B pathway, which is activated by mut-CARD14²⁰ (Fig. S6i).
142 Therefore, we examined γ H2AX levels in HU-treated cell lines with or without an
143 inhibitor of κ B (I κ B) overexpression which suppresses NF- κ B activation (Fig. S6j).
144 Notably, I κ B α overexpression partially reduced γ H2AX levels in the cells expressing
145 mut-CARD14 (Fig. 2e). Mut-CARD14-induced alteration of the RSR is partially
146 explained by activation of the NF- κ B signalling pathway.

147

148 **HR activation by mutant CARD14**

149 Having confirmed that mut-CARD14 expression decreases fork stability under
150 prolonged replication stress, we investigated whether HR-related factors are activated
151 under those circumstances. We approached this issue using a FACS-based method to
152 quantify the activities of HR-related factors at the single cell level^{29,30}. For these
153 analyses, the mean values of signal intensities obtained from HU-treated and Dox-
154 absent samples were set to threshold levels and the percentages of cells showing
155 intensities above these levels (γ H2AX^{hi} cells) were compared among samples (Fig. 3a, b
156 and Fig. S7a). Notably, consistent with immunoblotting data, mut-CARD14 cell lines
157 treated with Dox and either HU or APH for 36 h, showed a significant increase in the
158 percentage of γ H2AX^{hi} cells to the total cells, compared to those without Dox, whereas
159 wt-CARD14 showed no increase (Fig. 3c and Fig. S7b-d). Similarly, under prolonged
160 replication stress, mut-CARD14 expression significantly increased the ratio of highly
161 phosphorylated RPA2 cells (p-RPA2^{hi} cells) (Fig. 3d). Furthermore, co-staining with
162 γ H2AX and p-RPA2 revealed that mut-CARD14 expression increased the proportion of
163 double-positive cells (γ H2AX^{hi}p-RPA2^{hi} cells) (Fig. 3b, e). Similarly, we identified that

164 mut-CARD14 also activated BRCA1, which is important for HR and fork restart³¹,
165 yielding a higher proportion of γ H2AX^{hip}-BRCA1^{hi} cells (Fig. 3f, g). We also examined
166 whether the ATR-CHK1 pathway, which stabilises replication forks and promotes
167 several types of fork restarts including a HR-mediated fork restart in RSR³², is activated
168 by mut-CARD14 under prolonged fork stalling. Mut-CARD14 significantly increased
169 the proportion of γ H2AX^{hip}-CHK1^{hi} cells as well as p-CHK1^{hi} cells (Fig. 3h, i).
170 Collectively, these results suggest that in mut-CARD14-expressing cells, collapsed
171 forks caused by prolonged stalling were repaired by the HR-mediated pathway via
172 activation of the ATR-CHK1 signalling pathway.

173

174 **Mutant CARD14 promotes BIR in RSR**

175 HR-mediated repair of stalled or collapsed forks may take place via 3 pathways:
176 synthesis-dependent strand annealing (SDSA), double Holliday junction (dHJ), and
177 BIR^{3,9} (Fig. S8a). BIR is initiated when only one broken end is available for strand
178 invasion, whereas SDSA and dHJ require two DSB ends. Thus, dormant origin firing is
179 essential for rescuing collapsed forks using these two pathways³. We sought to
180 determine which pathway played a dominant role in replication fork repair under mut-
181 CARD14 expression. To this end, we first performed quantitative PCR (qPCR) analysis
182 of replication-related genes. The expression levels of genes associated with replication
183 origin firing, such as *ORC1*, *MCM10*, *GINS1*, and *GINS2*, were decreased in mut-
184 CARD14-expressing cells following extended HU treatment, but not in wt-CARD14-
185 expressing cells (Fig. S9a-h). To further confirm whether mut-CARD14 suppresses new
186 origin firing after prolonged fork stalling, we analysed replication fork dynamics via
187 DNA fibre assay with prolonged HU treatment. The frequency of new origin firing was

188 reduced by mut-CARD14 expression but not by wt-CARD14, while neither wt- nor
189 mut-CARD14 altered the frequency of stalled or ongoing replication forks (Fig. 4a-d).
190 As these findings suggested that mut-CARD14 expression, together with HU, inhibits
191 dormant origin firings near collapsed forks, resulting in a situation where only one
192 broken end is available for DSB repair, we concluded that mut-CARD14 promotes BIR
193 in stalled or collapsed fork repair under conditions of replication stress (Fig. S8b).
194 Notably, HR-mediated revertant epidermis samples as well as SCC samples, obtained
195 from the studied CAPE patients, all possessed long-tract LOH extending from
196 recombination sites to the telomere (Fig. 1d and Fig. S2b, d-f). Although this specific
197 form of LOH arises only via BIR or dHJ with crossover resolution (Fig. S8c), other
198 possible consequences of dHJ, such as gene conversion, were not detected in any of the
199 samples. Furthermore, the frequency of sister chromatid exchanges (SCEs)³³, which
200 represents the crossover events, following HU treatment was somewhat decreased in
201 mut-CARD14-expressing cells, but not in those expressing wt-CARD14 (Fig. 4e-g),
202 suggesting that dHJ with crossover does not mainly occur in this context. Considering
203 the results together, we deduced that mut-CARD14 plays a role in the reversion of a
204 disease-causing mutation in patients with CAPE, by enhancing BIR under conditions of
205 replication stress (Fig. 4h).

206

207 **Discussion**

208 The current study revealed, for the first time, that RM occurs in CAPE. We
209 demonstrated that HR is the major mechanism responsible for the reversion of *CARD14*
210 mutations and that mut-CARD14 preferentially drives BIR under conditions of
211 replication stress. However, BIR is generally regarded as a rare event which is

212 suppressed by MUS81 endonuclease in normal cells, as well as converging forks
213 arriving from the opposite direction, as it elevates the risk of mutagenesis and
214 chromosomal abnormalities³⁴. Notably, recent studies have uncovered a series of
215 unusual BIR-promoting circumstances as follows^{3,35-40}: (i) generation of DNA nicks in
216 genomic regions lacking replication origins within a MUS81-null background, (ii)
217 repair of massive replication fork collapse under conditions of replication stress (e.g.,
218 overexpression of oncogenes, deregulation of origin licensing, inverted DNA repeats,
219 trinucleotide repeats, and R-loops), and (iii) alternative lengthening of telomeres in the
220 absence of telomerase. Our findings suggest that mut-CARD14 promotes replication
221 fork collapse and suppresses dormant origin firing in the replication stress state. These
222 effects of mut-CARD14 collectively promote BIR that may continue for hundreds of
223 kilobases, resulting in long-tract LOH that extends to the telomere. Therefore, to our
224 knowledge, this study is the first to provide evidence indicating the potential
225 contribution of BIR to RM. Notably, similar long-tract LOH has also been frequently
226 observed in other skin diseases such as ichthyosis with confetti and loricrin keratoderma
227 where dozens to thousands of HR-driven revertant skin spots arise in each patient¹⁴⁻¹⁸.
228 Further investigations centred on RM may help elucidate hitherto unknown or unvalued
229 mechanisms that regulate the BIR pathway.

230 This study also suggests that skin inflammation such as that induced by mut-CARD14
231 may promote BIR. Recent studies on patients with ulcerative colitis have revealed that
232 human intestinal stem cells exposed to long-standing inflammation adapt to such
233 inflammation by acquiring genetic and genomic alterations including LOH, associated
234 with the downregulation of IL-17 signalling^{11,12}. Furthermore, long-tract LOH is
235 frequently seen in skin lesions of porokeratosis, a common autoinflammatory

236 keratinisation disease⁴¹. Interestingly, previous studies have shown that it is replication
237 stress, and not I-SceI-induced DSB, which activates the NF- κ B signalling pathway,
238 which, in turn, induces HR⁴². The current study indicated that mut-CARD14 does not
239 promote HR when DSBs are exogenously introduced via I-SceI but drives BIR under
240 conditions of replication stress. These findings suggest that inflammation resulting from
241 NF- κ B activation under conditions of replication stress may induce BIR. Further studies
242 are warranted to address the involvement of inflammation in BIR initiation.

243 In conclusion, this study demonstrated that RM occurs in CAPE and implicates the
244 involvement of BIR in reversion events. Fully elucidating the molecular mechanisms
245 underlying natural gene therapy may deepen the understanding of DDR or RSR and
246 pave the way to develop innovative therapies for genetic diseases, for which therapeutic
247 options are currently limited, by manipulating HR to repair disease-causing mutations.

248

249 **References**

- 250 1. Jonkman, M. F. & Pasmooij, A. M. G. Revertant Mosaicism — Patchwork in
251 the Skin. *N. Engl. J. Med.* **360**, 1680–1682 (2009).
- 252 2. Nomura, T. Recombination-induced revertant mosaicism in ichthyosis with
253 confetti and loricrin keratoderma. *J. Dermatol. Sci.* **97**, 94–100 (2020).
- 254 3. Kramara, J., Osia, B. & Malkova, A. Break-Induced Replication: The Where,
255 The Why, and The How. *Trends Genet.* **34**, 518–531 (2018).
- 256 4. Khanna, K. K. & Jackson, S. P. DNA double-strand breaks: signaling, repair
257 and the cancer connection. *Nat. Genet.* **27**, 247–254 (2001).
- 258 5. Mazouzi, A., Velimezi, G. & Loizou, J. I. DNA replication stress: causes,
259 resolution and disease. *Exp. Cell Res.* **329**, 85–93 (2014).
- 260 6. Zeman, M. K. & Cimprich, K. A. Causes and consequences of replication
261 stress. *Nat. Cell Biol.* **16**, 2–9 (2014).
- 262 7. Petermann, E., Orta, M. L., Issaeva, N., Schultz, N. & Helleday, T.
263 Hydroxyurea-stalled replication forks become progressively inactivated and
264 require two different RAD51-mediated pathways for restart and repair. *Mol.*
265 *Cell* **37**, 492–502 (2010).
- 266 8. Petermann, E. & Helleday, T. Pathways of mammalian replication fork
267 restart. *Nat. Rev. Mol. Cell Biol.* **11**, 683–687 (2010).
- 268 9. Jasin, M. & Rothstein, R. Repair of Strand Breaks by Homologous
269 Recombination. *Cold Spring Harb. Perspect. Biol.* **5**, a012740 (2013).
- 270 10. Deng, G., Lu, Y., Zlotnikov, G., Thor, A. D. & Smith, H. S. Loss of
271 Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas. *Science*
272 **274**, 2057–2059 (1996).

- 273 11. Kakiuchi, N. *et al.* Frequent mutations that converge on the NFKBIZ
274 pathway in ulcerative colitis. *Nature* **577**, 260–265 (2020).
- 275 12. Nanki, K. *et al.* Somatic inflammatory gene mutations in human ulcerative
276 colitis epithelium. *Nature* **577**, 254–259 (2020).
- 277 13. Revy, P., Kannengiesser, C. & Fischer, A. Somatic genetic rescue in
278 Mendelian haematopoietic diseases. *Nat. Rev. Genet.* **20**, 582–598 (2019).
- 279 14. Choate, K. A. *et al.* Mitotic Recombination in Patients with Ichthyosis
280 Causes Reversion of Dominant Mutations in KRT10. *Science* **330**, 94–97
281 (2010).
- 282 15. Choate, K. A. *et al.* Frequent somatic reversion of KRT1 mutations in
283 ichthyosis with confetti. *J. Clin. Invest.* **125**, 1703–1707 (2015).
- 284 16. Suzuki, S. *et al.* Revertant Mosaicism in Ichthyosis with Confetti Caused by a
285 Frameshift Mutation in KRT1. *J. Invest. Dermatol.* **136**, 2093–2095 (2016).
- 286 17. Nomura, T. *et al.* Chromosomal inversions as a hidden disease-modifying
287 factor for somatic recombination phenotypes. *JCI Insight* **3**, e97595 (2018).
- 288 18. Suzuki, S. *et al.* Somatic recombination underlies frequent revertant
289 mosaicism in lorincrin keratoderma. *Life Sci. Alliance* **2**, e201800284 (2019).
- 290 19. Craiglow, B. G. *et al.* CARD14-associated papulosquamous eruption: A
291 spectrum including features of psoriasis and pityriasis rubra pilaris. *J. Am.*
292 *Acad. Dermatol.* **79**, 487–494 (2018).
- 293 20. Howes, A. *et al.* Psoriasis mutations disrupt CARD14 autoinhibition
294 promoting BCL10-MALT1-dependent NF- κ B activation. *Biochem. J.* **473**,
295 1759–1768 (2016).

- 296 21. Dainichi, T. *et al.* The epithelial immune microenvironment (EIME) in atopic
297 dermatitis and psoriasis. *Nat. Immunol.* **19**, 1286–1298 (2018).
- 298 22. Takeichi, T. *et al.* Pityriasis Rubra Pilaris Type V as an Autoinflammatory
299 Disease by CARD14 Mutations. *JAMA Dermatol.* **153**, 66–70 (2017).
- 300 23. Arita, K. *et al.* Squamous cell carcinoma in a patient with non-bullous
301 congenital ichthyosiform erythroderma. *Br. J. Dermatol.* **148**, 367–369
302 (2003).
- 303 24. Natsuga, K. *et al.* Novel ABCA12 mutations identified in two cases of non-
304 bullous congenital ichthyosiform erythroderma associated with multiple skin
305 malignant neoplasia. *J. Invest. Dermatol.* **127**, 2669–2673 (2007).
- 306 25. Symington, L. S. & Gautier, J. Double-strand break end resection and repair
307 pathway choice. *Annu. Rev. Genet.* **45**, 247–271 (2011).
- 308 26. Panier, S. & Boulton, S. J. Double-strand break repair: 53BP1 comes into
309 focus. *Nat. Rev. Mol. Cell Biol.* **15**, 7–18 (2014).
- 310 27. Byrne, B. M. & Oakley, G. G. Replication protein A, the laxative that keeps
311 DNA regular: The importance of RPA phosphorylation in maintaining
312 genome stability. *Semin. Cell Dev. Biol.* **86**, 112–120 (2019).
- 313 28. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes
314 homology-directed repair of DNA damage in mammalian cells. *Genes Dev.*
315 **13**, 2633–2638 (1999).
- 316 29. Shibata, A. *et al.* DNA double-strand break repair pathway choice is directed
317 by distinct MRE11 nuclease activities. *Mol. Cell* **53**, 7–18 (2014).

- 318 30. Forment, J. V. & Jackson, S. P. A flow cytometry-based method to simplify
319 the analysis and quantification of protein association to chromatin in
320 mammalian cells. *Nat. Protoc.* **10**, 1297–1307 (2015).
- 321 31. Xu, Y. *et al.* 53BP1 and BRCA1 control pathway choice for stalled
322 replication restart. *Elife* **6**, 1–24 (2017).
- 323 32. Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR:
324 ensuring faithful duplication of a challenging genome. *Nat. Rev. Mol. Cell*
325 *Biol.* **18**, 622–636 (2017).
- 326 33. Wilson, D. M. & Thompson, L. H. Molecular mechanisms of sister-
327 chromatid exchange. *Mutat. Res.* **616**, 11–23 (2007).
- 328 34. Mayle, R. *et al.* Mus81 and converging forks limit the mutagenicity of
329 replication fork breakage. *Science* **349**, 742–747 (2015).
- 330 35. Lydeard, J. R., Jain, S., Yamaguchi, M. & Haber, J. E. Break-induced
331 replication and telomerase-independent telomere maintenance require Pol32.
332 *Nature* **448**, 820–823 (2007).
- 333 36. Anand, R. P., Lovett, S. T. & Haber, J. E. Break-Induced DNA Replication.
334 *Cold Spring Harb. Perspect. Biol.* **5**, a010397 (2013).
- 335 37. Kramara, J., Osia, B. & Malkova, A. Break-induced replication: an unhealthy
336 choice for stress relief? *Nat. Struct. Mol. Biol.* **24**, 11–12 (2017).
- 337 38. Sakofsky, C. J. & Malkova, A. Break induced replication in eukaryotes:
338 mechanisms, functions, and consequences. *Crit. Rev. Biochem. Mol. Biol.* **52**,
339 395–413 (2017).

- 340 39. Kim, J. C., Harris, S. T., Dinter, T., Shah, K. A. & Mirkin, S. M. The role of
341 break-induced replication in large-scale expansions of (CAG)_n/(CTG)_n
342 repeats. *Nat. Struct. Mol. Biol.* **24**, 55–60 (2017).
- 343 40. Macheret, M. & Halazonetis, T. D. Intragenic origins due to short G1 phases
344 underlie oncogene-induced DNA replication stress. *Nature* **555**, 112–116
345 (2018).
- 346 41. Kubo, A. *et al.* Clonal Expansion of Second-Hit Cells with Somatic
347 Recombinations or C>T Transitions Form Porokeratosis in MVD or MVK
348 Mutant Heterozygotes. *J. Invest. Dermatol.* **139**, 2458–2466.e9 (2019).
- 349 42. Volcic, M. *et al.* NF-κB regulates DNA double-strand break repair in
350 conjunction with BRCA1–CtIP complexes. *Nucleic Acids Res.* **40**, 181–195
351 (2012).
- 352
- 353

354 **Methods**

355 **Human subjects and study approval**

356 Patients participating in the study provided written informed consent, in compliance
357 with the Declaration of Helsinki. This study was approved by the Institutional Review
358 Board of the Hokkaido University Graduate School of Medicine (project No. 14-063).
359 Both patients provided a peripheral blood or saliva sample and skin samples from
360 affected skin and revertant spots.

361

362 **Genomic DNA extraction**

363 For mutation analysis, genomic DNA from the patients' peripheral blood or saliva was
364 extracted using a QIAamp DNA Blood Maxi Kit (Qiagen) or an Oragene DNA Self-
365 Collection Kit (DNA Genotek), respectively. Genomic DNA was also extracted from
366 the patients' skin using a QIAamp DNA Micro Kit (Qiagen) after separating the
367 epidermis from the dermis of punch-biopsied skin samples using an ammonium
368 thiocyanate solution, as described previously⁴³.

369

370 **Sanger sequencing**

371 Exons and exon-intron boundaries in *CARD14* were amplified via PCR using AmpliTaq
372 Gold PCR Master Mix (ThermoFisher Scientific). Primer sequences and PCR
373 conditions are available upon request. PCR amplicons were treated with ExoSAP-IT
374 reagent (Affymetrix), and the sequencing reaction was performed using BigDye
375 Terminator version 3.1 (ThermoFisher Scientific). Sequence data were obtained using
376 an ABI 3130xl genetic analyser (Applied Biosystems).

377

378 **Whole-genome oligo-SNP array**

379 CytoScan HD Array (Affymetrix) was used to identify copy number variations (CNVs)
380 and LOHs using genomic DNA extracted from the epidermis (outsourced to RIKEN
381 Genesis). All experimental procedures were conducted according to the manufacturer's
382 instructions. Briefly, 250 ng of each genomic DNA sample was digested with Nsp I and
383 ligated to adaptors, followed by PCR amplification. Following purification,
384 fragmentation, and biotinylation of the PCR products, these samples were hybridised to
385 the Affymetrix CytoScan HD Array. After washing and staining, fluorescent signals
386 were obtained with a GeneChip Scanner 3000 7G (Affymetrix) and GeneChip
387 Command Console (Affymetrix). The data were then analysed using Chromosome
388 Analysis Suite Software 4.0 (Affymetrix) by filtering CNVs with a minimum size of
389 400 kbp and 50 consecutive markers and LOHs with a minimum size of 3,000 kbp and
390 50 consecutive markers.

391

392 **Cell culture, X-irradiation, and drug treatment**

393 U2OS (ATCC), the human osteosarcoma cell line, and HaCaT (CLS Cell Lines
394 Service), the commercially available immortalised human keratinocyte cell line, were
395 cultured in Dulbecco's modified Eagle medium (Nacalai Tesque) supplemented with
396 10% foetal bovine serum (Sigma-Aldrich) and with or without 1% Antibiotic
397 Antimycotic Solution (Sigma-Aldrich). To examine the response to X-irradiation, 150
398 kV X-ray was delivered at 20 mA with 1 mm aluminium filter at a distance of 350 mm
399 from the cell surface. To analyse the response to etoposide, cells were treated with 10 or
400 250 μ M etoposide (Sigma-Aldrich) for indicated time periods since etoposide was
401 reported to induce two types of DNA damage mechanisms depending on its

402 concentration⁴⁴. To investigate the response to HU and APH, cells were treated with 2
403 mM HU (Sigma-Aldrich) and 2 µg/mL APH (Sigma-Aldrich) for indicated time
404 periods, respectively. The cells were then washed with phosphate-buffered saline (PBS)
405 (Nacalai Tesque) before addition of drug-free medium and incubated as necessary.

406

407 **RNA extraction and quantitative real-time reverse transcription PCR**

408 RNA extraction and reverse transcription were performed using a SuperPrep II Cell
409 Lysis & RT Kit for qPCR (Toyobo). Quantitative real-time PCR was carried out using
410 the QuantStudio 12K Flex Real Time PCR System (ThermoFisher Scientific) with
411 TaqMan Fast Advanced Master Mix (ThermoFisher Scientific) and TaqMan MGB
412 probes (ThermoFisher Scientific) according to the manufacturer's instructions. To
413 assess the expression levels of CARD14 and inflammatory chemokines, the following
414 TaqMan probes were used: *CARD14* (Hs01106900_m1), *CXCL8* (Hs00174103_m1),
415 and *CCL20* (Hs00355476_m1). For the analysis of replication-related genes, Custom
416 TaqMan Array Cards (ThermoFisher Scientific) were used. Target genes and their
417 corresponding TaqMan probes were as follows; *ORC1* (Hs01069758_m1), *ORC6*
418 (Hs00941233_g1), *MCM2* (Hs01091564_m1), *MCM7* (Hs00428518_m1), *MCM10*
419 (Hs00218560_m1), *CDC6* (Hs00154374_m1), *CDC45* (Hs00907337_m1), *CDT1*
420 (Hs00925491_g1), *TOP3A* (Hs00172806_m1), *TOP3B* (Hs00172728_m1), *TOPBP1*
421 (Hs00199775_m1), *RECQL4* (Hs00171627_m1), *GINS1* (Hs01040834_m1), *GINS2*
422 (Hs00211479_m1), *GINS3* (Hs01090589_m1), *GINS4* (Hs01077879_m1), *TIPIN*
423 (Hs00762756_s1), *CLSPN* (Hs00898637_m1), *WDHD1* (Hs00173172_m1), *PCNA*
424 (Hs00427214_g1), *POLA1* (Hs00213524_m1), *POLD1* (Hs01100821_m1), *POLE*
425 (Hs00923952_m1), *BODILI* (Hs00386033_m1), and *RFC1* (Hs01099126_m1).

426 Following comprehensive analyses, expression levels of some genes were confirmed
427 using separately prepared samples. Expression values were normalised to *ACTB*
428 (Hs01060665_g1) levels, and relative expression levels were calculated using the $\Delta\Delta C_t$
429 method.

430

431 **Plasmids and transfection**

432 Wild-type *CARD14* cDNA (pFN21AE3344) was purchased from the Kazusa DNA
433 Research Institute. To generate *CARD14*-expressing vector (p3FLAG-CARD14wt) for
434 transient overexpression, *EGFP* in pEGFP-C2 (Takara Bio) was replaced by the wild-
435 type *CARD14* gene obtained from pFN21AE3344 with N-terminal 3xFLAG tag
436 peptides (DYKDHDGDYKDHDIDYKDDDDK) (Sigma-Aldrich). To generate
437 *CARD14*-expressing vector (pTRE3G-Pur-3FLAG-CARD14wt) for establishment of
438 Tet-On 3G inducible cell lines, the wild-type *CARD14* insert with N-terminal 3xFLAG
439 tag was cloned into pBApo-EFalpha Pur DNA (Takara Bio) whose EF-1 α promoter was
440 replaced by TRE3G promoter obtained from pTRE3G (Clontech). The c.356T>C or
441 c.407A>T mutation was introduced both into p3FLAG-CARD14wt and pTRE3G-Pur-
442 3FLAG-CARD14wt using QuikChange Lightning Site-Directed Mutagenesis Kits
443 (Agilent Technologies) (p3FLAG-CARD14-M119T /-Q136L or pTRE3G-Pur-3FLAG-
444 CARD14-M119T /-Q136L, respectively). To establish Tet3G-expressing U2OS cells,
445 pCMV-Tet3G (Clontech) was used. For the NF- κ B-Luciferase Reporter assay,
446 pNL1.1.PGK[*Nluc*/PGK] (Promega), pGL4.27[*luc2P*/minP/Hygro] (Promega), and
447 pNL3.2.NF- κ B-RE[*NlucP*/NF- κ B-RE/Hygro] (Promega) were purchased, and pCMV4-
448 3 HA/I κ B-alpha was a gift from Warner Greene (Addgene, #21985). To generate firefly
449 luciferase (*Fluc*)-expressing vector (pNL1.1.PGK[*Fluc*/PGK]) for transfection

450 efficiency normalisation, *Nanoluc luciferase* (Nluc) gene in pNL1.1.PGK[*Nluc*/PGK]
451 was replaced by *Fluc* gene obtained from pGL4.27[*luc2P*/minP/Hygro]. pDRGFP
452 (Addgene, #26475) and pCBASceI (Addgene, #26477) were gifts from Maria Jasin for
453 DR-GFP assay. To generate wild-type EGFP-expressing vector (pDRGFPwt) for
454 transfection efficiency normalisation, *Sce-EGFP* gene, which contains an I-SceI
455 recognition sequence, was replaced by *EGFP* gene obtained from pEGFP-C2. All
456 plasmids were transfected into U2OS or HaCaT cells using Lipofectamine 3000
457 (ThermoFisher Scientific) or Xfect Transfection Reagent (Takara) according to the
458 manufacturer's instructions.

459

460 **Establishment of the Tet-On 3G CARD14 inducible cell lines**

461 The Tet-On 3G Inducible Expression System (Clontech) was used according to the
462 manufacturer's instructions to establish Tet-On 3G CARD14 inducible cell lines.
463 Briefly, U2OS cells were first transfected with the pCMV-Tet3G plasmid and selected
464 using 250 µg/ml G418 (Sigma-Aldrich). The G418-resistant clone was maintained as
465 the Tet3G-expressing U2OS cell line. Tet3G-expressing U2OS cells were then
466 transfected with pTRE3G-Pur-3FLAG-CARD14wt, pTRE3G-Pur-3FLAG-CARD14-
467 M119T, or pTRE3G-Pur-3FLAG-CARD14-Q136L. Next, 0.75 µg/µl puromycin
468 (Gibco) was used for selection following which double-stable Tet-On 3G inducible cell
469 lines were cloned by limiting the dilution technique. The cell lines of each genotype
470 were tested for CARD14 expression in the presence of 500 ng/ml Dox (Clontech), and
471 clones with the highest fold induction were selected for further analyses.

472

473

474 **Immunofluorescence staining and microscopy**

475 Twenty-four hours after adding Dox into CARD14 inducible cell lines, or 24 h after
476 transfection into U2OS or HaCaT cells, cells were fixed in 4% paraformaldehyde in
477 PBS for 10 min at 4°C and washed twice with PBS. After permeabilization with 0.5%
478 Triton X-100 in PBS for 10 min at 4°C and blocking with 3% bovine serum albumin
479 (BSA) (Wako) in PBS with 1% DAPI (Sigma-Aldrich) at 37°C, the cells were
480 incubated with primary and secondary antibodies diluted with 3% BSA in PBS for 60
481 min (primary antibodies) or for 30 min (secondary antibodies) at 37°C. Anti-FLAG M2
482 antibodies (Sigma-Aldrich, F3165) were used as the primary antibodies for FLAG
483 staining. Alexa Fluor 488-conjugated goat anti-mouse IgG (H + L) (ThermoFisher
484 Scientific, A11001) and Alexa Fluor 647-conjugated goat anti-mouse IgG (H + L)
485 (ThermoFisher Scientific, A21244) were used as secondary antibodies. For F-actin
486 staining, the cells were incubated with Alexa Fluor 488 Phalloidin (ThermoFisher
487 Scientific) for 20 min at 37°C between the primary and secondary antibody reactions.
488 Nuclei were stained with DAPI during the blocking step. Fluorescence images were
489 obtained with a BZ-X800 (Keyence) or FV1000 confocal laser scanning microscope
490 (Olympus).

491

492 **NF-κB-Luciferase Reporter assay**

493 CARD14 inducible cell lines were co-transfected with pNL3.2.NF-κB-RE[*NlucP*/NF-
494 κB-RE/Hygro] and pNL1.1.PGK[*Fluc*/PGK] in the absence or presence of Dox. To
495 evaluate the effect of IκBα expression on the NF-κB signalling pathway, pCMV4-3
496 HA/IκB-alpha was overexpressed using pNL3.2.NF-κB-RE[*NlucP*/NF-κB-RE/Hygro]
497 and pNL1.1.PGK[*Fluc*/PGK]. Luciferase activity of the lysates was measured using a

498 Nano-Glo Dual-Luciferase Reporter Assay System (Promega) and SpectraMax
499 Paradigm (Molecular Devices) according to the manufacturer's instructions. Nluc
500 activity derived from pNL3.2.NF- κ B-RE[*NlucP*/NF- κ B-RE/Hygro] was normalised to
501 Fluc activity from pNL1.1.PGK[*Fluc*/PGK].

502

503 **Western blotting**

504 The whole cell lysate was obtained by lysing cells in a mixture of NuPAGE LDS
505 Sample Buffer (ThermoFisher Scientific) and NuPAGE Sample Reducing Agent
506 (ThermoFisher Scientific). The lysate was sonicated with Handy Sonic UR-21P
507 (TOMY), denatured for 10 min at 70°C, and fractionated on NuPAGE 4-12% Bis-Tris
508 Protein Gels (ThermoFisher Scientific), followed by the transferring of resolved
509 proteins onto PVDF membranes via an iBlot 2 Dry Blotting System (ThermoFisher
510 Scientific). Following blocking for 60 min with 1% BSA in TBST (10 mM Tris-HCl
511 (pH7.4), 150 mM NaCl, 0.05% Tween 20) or 5% skim milk in TBST, membranes were
512 incubated overnight at 4°C with one of the following primary antibodies: FLAG
513 (Sigma-Aldrich, F3165), γ H2AX (Millipore, 05-636), histone H3 (abcam, ab1791),
514 RPA32 (RPA2) (Santa Cruz Biotechnology, sc-56770), phospho-RPA2 (Ser33) (Novus
515 Biologicals, NB100-544), 53BP1 (Cell Signaling Technology, 4937), phospho-53BP1
516 (Ser1778) (Cell Signaling Technology, 2675), BRCA1 (Santa Cruz Biotechnology, sc-
517 6954), or phospho-BRCA1 (Ser1524) (Cell Signaling Technology, 9009). HRP-linked
518 horse anti-mouse IgG (Cell Signaling Technology, 7076) and HRP-linked goat anti-
519 rabbit IgG (Cell Signaling Technology, 7074) were used as secondary antibodies. 20X
520 LumiGLO Reagent and 20X Peroxide (Cell Signaling Technology) or SuperSignal
521 West Dura Extended Duration Substrate (ThermoFisher Scientific) were used as a

522 substrate for the secondary antibodies. Chemiluminescence data were obtained with
523 ImageQuant LAS 4000 (Fujifilm) and band intensities were quantified using Image J
524 software (NIH).

525

526 **DR-GFP assay (I-SceI induced DSB repair assay)**

527 CARD14 inducible cell lines were used in a DR-GFP assay via transient transfection
528 with pDRGFP and pCBASceI. Cells were harvested 72 h after transfection with these
529 two plasmids, following which the number of EGFP-positive cells was measured using
530 FACSCanto II (BD Biosciences) (30,000 cells per biological replicate were analysed).
531 Under these conditions, parallel transfection with the pDRGFPwt plasmid was used to
532 determine transfection efficiency. All analyses were performed in the absence or
533 presence of Dox. Cells not transfected with pCBASceI were used as negative control. A
534 DR-GFP assay using U2OS cells which harbour chromosomally integrated EGFP
535 reporter substrates was also conducted. To establish this cell line, U2OS cells were first
536 transfected with pDRGFP plasmid, selected using 0.75 µg/µl puromycin and cloned via
537 the limiting dilution technique (U2OS_DRGFP cells). U2OS_DRGFP cells were
538 transfected with p3FLAG-CARD14-WT, p3FLAG-CARD14-M119T, or p3FLAG-
539 CARD14-Q136L along with pCBASceI. Cells were harvested 72 h after transfection
540 and the number of EGFP-positive cells were counted using FACSCanto II. HR
541 efficiency was calculated as the ratio of EGFP-positive cells over total cells. Non-
542 transfected cells were used as negative control. All flow cytometry data were analysed
543 using FlowJo software (BD Biosciences).

544

545 **Cell cycle analysis by FACS**

546 To analyse cell cycle distribution, cells were pulse labelled with 10 μ M EdU 30 min
547 before harvest. EdU staining was performed using a Click-iT Plus EdU Alexa Fluor 647
548 Flow Cytometry Assay Kit (ThermoFisher Scientific) according to the manufacturer's
549 instructions. Genomic DNA was stained with FxCycle Violet (ThermoFisher
550 Scientific). Flow cytometry data of EdU-DNA content profiles were acquired with
551 FACSCanto II and analysed using FlowJo software.

552

553 **FACS-based quantification of DNA damage and HR-related factor activity**

554 Cells treated with or without HU were trypsinised and washed with 1% BSA in PBS
555 and fixed in 4% paraformaldehyde in PBS for 15 min at room temperature, followed by
556 incubation with dilution buffer (0.5% BSA, 0.1% Triton X-100 in PBS) for 30 min at
557 room temperature. Cells were then incubated for 30 min at room temperature with one
558 or two of the following primary antibodies diluted with dilution buffer: γ H2AX
559 (Millipore, 05-636), phospho-RPA2 (Ser33) (Novus Biologicals, NB100-544),
560 phospho-BRCA1 (Ser1524) (Cell Signaling Technology, 9009), or phospho-Chk1
561 (Ser345) (abcam, ab47318). After washing with dilution buffer, cells were subsequently
562 incubated with Alexa Fluor 488-conjugated goat anti-mouse IgG (H + L) and/or Alexa
563 Fluor 647-conjugated goat anti-rabbit IgG (H + L) as secondary antibodies. Genomic
564 DNA was stained with FxCycle Violet. A gate was established for each factor using
565 negative control samples stained with mouse IgG1 negative control antibodies (BIO-
566 RAD, MCA928) or polyclonal rabbit IgG (R&D Systems, AB-105-C). In all analyses,
567 signal intensities of 30,000 cells per biological replicate were measured using
568 FACSCanto II and analysed with FlowJo software.

569

570 **DNA fibre assay**

571 The DNA fibre assay was performed as described previously⁴⁵ with slight
572 modifications. Briefly, CARD14 inducible cell lines were labelled with 25 μ M 5-
573 chlorodeoxyuridine (CldU) (Sigma-Aldrich), washed with PBS, and exposed to 250 μ M
574 5-iododeoxyuridine (IdU) (Sigma-Aldrich). To measure the efficiency of replication
575 restart, cells were treated with 2 mM HU after CldU labelling and exposed to IdU.
576 Labelled cells were harvested and resuspended in cold PBS. The cell suspension was
577 mixed 1:4 with cell lysis solution (0.5% SDS, 50 mM EDTA, 200 mM Tris-HCl pH
578 8.0), placed on glass slides and carefully tilted at a 15° angle causing DNA fibres to
579 spread into single molecules via gravity. Next, the DNA fibres were denatured by fixing
580 with 4% paraformaldehyde in PBS and immersing in 2.5 M HCl for 80 min at 27°C.
581 Slides were neutralised and washed with PBS before blocking with 3% BSA in PBS for
582 30 min at 37°C. DNA fibres were then incubated with primary and secondary antibodies
583 diluted in 3% BSA in PBS overnight at 4°C (primary antibodies) or for 90 min at 37°C
584 (secondary antibodies). Anti-BrdU antibodies [BU1/75 (ICR1)] (abcam, ab6326) for
585 CldU and anti-BrdU antibodies [clone B44] (BD Biosciences, 347580) for IdU were
586 used as primary antibodies. Alexa Fluor 488-conjugated goat anti-rat IgG (H + L)
587 antibodies and Alexa Fluor 594-conjugated goat anti-mouse IgG (H + L) antibodies
588 (ThermoFisher Scientific, A11005) were used as secondary antibodies. Finally, slides
589 were mounted in ProLong Diamond Antifade Mountant (ThermoFisher Scientific).
590 Images were obtained using a FV1000 confocal laser scanning microscope (Olympus)
591 and all data were analysed via Computer Assisted Scoring & Analysis (CASA) software
592 purchased from Dr. Paul Chastain. Tracts containing CldU were pseudocoloured in red

593 and tracts containing IdU were green. Replication fork speed was estimated using a
594 conversion factor of 2.59 kb/mm⁴⁶.

595

596 **SCE assay**

597 The SCE assay was carried out essentially as previously described⁴⁷. Prior to the
598 experiment, slides were immersed in 0.1 N HCl in 99.5% ethanol for 20 min at room
599 temperature and washed thrice with 99.5% ethanol. After rinsing with distilled water,
600 they were stored in distilled water at 4°C. Cells were incubated with 20 µM BrdU
601 (Sigma-Aldrich) for 42 h. During the last 2 h of BrdU incubation, cells were also treated
602 with 0.2 µg/ml colcemid (Sigma-Aldrich). To examine the effects of replication stress,
603 cells were incubated with BrdU for 20 h followed by 2 mM HU treatment for 36 h,
604 incubated again with BrdU for 24 h and treated with colcemid for the last 2 h. Cells
605 were collected by mitotic shake-off, washed in PBS and swollen in 7 ml of hypotonic
606 solution (46.5 mM KCl, 8.5 mM Na-Citrate) for 13 min at 37 °C. After the incubation, 2
607 ml of freshly prepared 3:1 methanol-acetic acid fixative was added and mixed by gently
608 inverting the tube. The tubes were centrifuged for 3 min at 200 x g at room temperature
609 and the supernatant was aspirated. The cell pellets were resuspended with 4 ml of
610 fixative and incubated for 20 min at 4°C. Following fixation, cells were resuspended in
611 a minimal amount of fixative. Metaphase cells were then spread on the chilled slides
612 described above and completely dried at room temperature. Slides were stained for 30
613 min at room temperature with 10 µg/ml Hoechst 33258 (Sigma-Aldrich) in Sorensen's
614 phosphate buffer (0.1 M Na₂HPO₄, 0.1 M KH₂PO₄, pH 6.8). After washing with
615 Sorensen buffer, the slides were covered with Sorensen buffer and exposed to UV light
616 for 60 min at 55°C, following which the slides were immersed in 1x SSC buffer

617 (ThermoFisher Scientific), incubated for 60 min at 50°C and finally stained with 10%
618 Gimsa (Wako) in Sorensen buffer for 30 min at room temperature. After washing thrice
619 with water, the coverslips were mounted on the slides using MOUNT-QUICK
620 (Funakoshi). Images were obtained via BZ-X800 (Keyence) using CFI Plan Apo λ
621 100xH objective lens. At least 25 images of each condition were randomly taken and
622 the number of SCEs per chromosome was scored.

623

624 **Quantification and statistical analysis**

625 Statistical parameters are shown in the figures and legends. Two-tailed t-tests or one-
626 way ANOVA with multiple comparisons tests were used for comparisons of means of
627 normally distributed data, whereas two-tailed Mann-Whitney U tests were used for
628 comparison of non-normally distributed data. All statistical analyses were conducted
629 using Prism 8.0 (GraphPad) and the threshold for defining statistical significance was P
630 < 0.05 .

631

632

633 **Methods References**

- 634 43. Clemmensen, A. *et al.* Extraction of high-quality epidermal RNA after
635 ammonium thiocyanate-induced dermo-epidermal separation of 4 mm human
636 skin biopsies. *Exp. Dermatol.* **18**, 979–984 (2009).
- 637 44. Tamaro, M., Barr, P., Ricci, B. & Yan, H. Replication-Dependent and
638 Transcription-Dependent Mechanisms of DNA Double-Strand Break Induction
639 by the Topoisomerase 2-Targeting Drug Etoposide. *PLoS One* **8**, e79202 (2013).

- 640 45. Nieminuszczy, J., Schwab, R. A. & Niedzwiedz, W. The DNA fibre technique –
641 tracking helicases at work. *Methods* **108**, 92–98 (2016).
- 642 46. Jackson, D. A. & Pombo, A. Replicon clusters are stable units of chromosome
643 structure: Evidence that nuclear organization contributes to the efficient
644 activation and propagation of S phase in human cells. *J. Cell Biol.* **140**, 1285–
645 1295 (1998).
- 646 47. Stults, D. M., Killen, M. W. & Pierce, A. J. The sister chromatid exchange (SCE)
647 assay. *Methods Mol. Biol.* **1105**, 439–455 (2014).
- 648

649 **Acknowledgements**


650 We are most indebted to the patients and their family members for their participation in
651 this study. This work was supported by the JSPS KAKENHI (Grant numbers:
652 JP19H03679 and JP17H06271 to T.N. and H.S., respectively), the Terumo Foundation
653 for Life Sciences and Arts (Grant number: 16-II 330 to T.N.), the Rohto Dermatology
654 Research Award (to T.N.), the Akiyama Life Science Foundation (to T.N.), the
655 Nakatomi Foundation (to T.N.), the Ichiro Kanehara Foundation (to T.N.), the Takeda
656 Science Foundation (to T.N.), the Geriatric Dermatology Research Grant (to T.N.), and
657 the Northern Advancement Center for Science & Technology (NOASTEC) Foundation
658 (Grant number: H28 T-1-42 to T.N.).

659

660 **Author Contributions**


661 T.M, S.S., and T.N. designed the study. K.N., Y.F., T.T., T.S., M. Ak., H.S., and T.N.
662 provided specimens. T.M. conducted the majority of the experiments and data analyses.
663 S.S. assisted with mutation analysis. S.S. and M.T. assisted with the DNA fibre assay.
664 M.T., J.T.P, and M.Ai. assisted with Western blot analysis. T.M. and T.N. wrote the
665 manuscript.

666



667 **Fig. 1. Clinical, histological, and genetic features of Case 1.**

668 **a**, Clinically normalised skin spots on the left lateral neck of Case 1. Dotted circles
669 represent the areas suspected of containing revertant spots. **b**, Histological and
670 schematic comparison among healthy control skin, affected skin, and revertant spots.
671 Haematoxylin and eosin staining. Scale bars, 100 μ m. SC, stratum corneum; G, granular
672 layer; S, spinous layer; B, basal layer; n, nucleus. See also Fig. S11-n. **c**, Skin sample
673 processing and mutation analysis of *CARD14* using genomic DNA. The missense
674 mutation, c.356T>C, is absent in the revertant epidermis (*). **d**, SNP array data of
675 chromosome 17 in Case 1. Cn-LOH was identified in all revertant epidermis samples
676 examined in this study. The dotted lines represent recombination breakpoints.
677



678 **Fig. 2. Mut-CARD14 expression alters the RSR.**

679 **a**, Intracellular distribution of CARD14 by immunofluorescence. Mut-CARD14 formed
680 aggregates in the perinuclear region, while wt-CARD14 was diffused in the cytoplasm.

681 Scale bar, 25 μ m. **b**, Gene expression levels of *CARD14* analysed by qPCR. *CARD14*
682 inducible cell lines were incubated in the presence or absence of Dox for 24 h. The
683 results were normalised to *ACTB* expression; n = 3 independent experiments; error bars

684 show s.e.m. **c**, *CARD14* inducible cell lines were incubated in the presence of Dox for
685 the indicated time periods. Whole-cell lysate was immunoblotted using the indicated
686 antibodies. HU-treated samples were used as positive controls exhibiting high levels of

687 γ H2AX. **d**, Schematic of cells being treated with 2 mM HU, and immunoblots showing
688 the levels of DNA damage following HU treatment. Prolonged HU treatment increased


689 γ H2AX in the presence of mut-CARD14. The relative band intensities of γ H2AX
690 following 36 h HU treatment are shown in the lower panel; NT, non-treatment. **e**,

691 Whole-cell lysate from cells treated with HU, with or without I κ B α overexpression, was
692 immunoblotted with indicated antibodies. I κ B α expression partially reduced γ H2AX

693 levels in cells expressing mut-CARD14. The band intensities of γ H2AX normalised to
694 Histone H3 are also shown. Statistical significance was calculated using two-tailed *t*-

695 test. **P* < 0.05, *****P* < 0.0001. ns, not significant.


696



697 **Fig. 3. FACS-based analyses of HR-related factors.**

698 **a**, Expression of γ H2AX (upper panels) and p-RPA2 (lower panels) in CARD14
699 inducible cell lines. Each panel is a representative histogram showing comparison
700 between non-treatment and 2 mM HU-treatment for 36 h with or without Dox. **b**, Red
701 and yellow lines are the threshold levels which were determined based on the mean
702 values of signal intensities obtained from HU-treated and Dox-absent cells. The
703 numbers in the upper and middle panels represent the percentage of γ H2AX^{hi} or p-
704 RPA2^{hi} cells, and those in the blue boxes in the lower panels represent γ H2AX^{hi}p-
705 RPA2^{hi} cells. **c**, Comparison of the percentage of γ H2AX^{hi} cells; n = 23 (WT) or 22
706 (M119T/Q136L) independent experiments. Error bars show s.e.m. **d, f, h**, Comparison
707 of the percentage of p-RPA2^{hi} (**d**), p-BRCA1^{hi} (**f**), and p-CBK1^{hi} cells (**h**). **e, g, i**,
708 Comparison of the percentage of γ H2AX^{hi}p-RPA2^{hi} cells (**e**), γ H2AX^{hi}p-BRCA1^{hi} cells
709 (**g**), and γ H2AX^{hi}p-CBK1^{hi} cells (**i**). n = 4-7 independent experiments. Error bars
710 represent s.e.m. Statistical significance was calculated using the two-tailed t-test. * P <
711 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001; ns, not significant.

712



713 **Fig. 4. Mut-CARD14 expression suppresses dormant origin firings and promotes**

714 **BIR.**

715 **a**, Schematic depicting timeline of when cells were labelled with CldU and IdU in the
716 presence of HU treatment. **b, c, d**, Quantification of the percentage of stalled forks (**b**),
717 new origin firings (**c**), and ongoing forks (**d**) to all CldU-labelled forks; $n = 6-12$
718 independent experiments; error bars show s.e.m. Statistical significance was calculated
719 using the two-tailed t-test. **e, f, g**, Quantification of SCE formation in cells treated with
720 or without HU. Quantification of SCE formation in cells treated with or without 2 mM
721 HU for 36 h. For each condition, 27-35 metaphase cells were analysed and each data
722 point represents the number of SCEs per 100 chromosomes per metaphase spread. Data
723 from 3 experiments were pooled. Horizontal lines represent mean values \pm s.e.m.
724 Statistical significance was calculated using one-way ANOVA followed by a multiple
725 comparisons test. **h**, A model of the mechanism underlying mitotic recombination
726 induced by mut-CARD14 expression. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, $****P <$
727 0.0001 ; ns, not significant.